| Literature DB >> 21785628 |
Saravanan Subramaniam1, Ramachandran Subramaniam, Suja Rajapandian, Subasini Uthrapathi, Victor Rajamanickam Gnanamanickam, Govinda Prasad Dubey.
Abstract
Atherosclerosis which results from gradual deposition of lipids in medium and large arteries is a leading cause of mortality worldwide. Terminalia arjuna is a herb of Combretaceae family which contains hypolipidemic compounds and flavonoids with high antioxidative properties. This study was conducted to determine the effect of ethanolic fraction of T. arjuna on blood lipids and atherosclerosis in rabbits fed with high fat diet (HFD). Twenty New Zealand rabbits of either sex were randomly divided into five groups: the first two were normal diet group and HFD (21% fat) group and the remaining three groups received high cholesterol diet supplemented with standard drug (Atorvastatin 10 mg kg(-1) body weight), T. arjuna ethanolic fraction (100 and 200 mg kg(-1) body weight), respectively. The concentration of total cholesterol (TC), low density lipoprotein (LDL) cholesterol, triglycerides (TGs), very low density lipoprotein (VLDL) cholesterol and high density lipoprotein (HDL) cholesterol was determined in rabbits at the start of the experiment, at the 14th, 30th days and at the end of the study. Anti-atherogenic index was calculated from the lipid profile of the rabbits before sacrifice. At the end of the experimental period, the aorta was removed for assessment of atherosclerotic plaques. Results show that T. arjuna significantly decreases TC, LDL and TG levels and increases HDL and lessens atherosclerotic lesion in aorta (P < .05). Hence T. arjuna extract can effectively prevent the progress of atherosclerosis. This is likely due to the effect of T. arjuna on serum lipoproteins and its antioxidant and anti-inflammatory properties.Entities:
Year: 2011 PMID: 21785628 PMCID: PMC3136348 DOI: 10.1093/ecam/neq003
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Composition of rabbit diet.
| Compositions | Normal diet (%) | HFD (%) |
|---|---|---|
| Moisture | 7.36 | 3.24 |
| Crude protein | 16.45 | 22.15 |
| Crude fat | 2.89 | 24.72 |
| Crude fiber | 12.24 | 3.6 |
| Calcium | 1.26 | 1.16 |
| Phosphorous | 0.85 | 0.86 |
| Total ash | 6.79 | 6.83 |
Figure 1GC-MS analysis showing the presence of plant sterols.
Serum lipid profile and atherogenic index.
| No. of days | Parameters | Control | D. Control | Std | EtOH 100 (mg kg−1) | EtOH 200 (mg kg−1) |
|---|---|---|---|---|---|---|
| Baseline | ||||||
| TC (mg dl−1) | 54.02 ± 1.99 | 53.42 ± 3.66 | 55.84 ± 3.44 | 54.91 ± 4.50 | 54.38 ± 3.04 | |
| HDL (mg dl−1) | 31.69 ± 1.95 | 30.03 ± 1.15 | 29.47 ± 1.50 | 26.62 ± 1.88 | 30.62 ± 2.16 | |
| LDL (mg dl−1) | 7.50 ± 3.41 | 5.86 ± 3.89 | 10.93 ± 3.62 | 14.13 ± 4.54 | 9.64 ± 2.06 | |
| VLDL (mg dl−1) | 14.83 ± 0.73 | 17.53 ± 0.48 | 15.44 ± 0.77 | 14.16 ± 0.66 | 14.12 ± 0.82 | |
| TG (mg dl−1) | 74.15 ± 3.65 | 87.63 ± 2.42 | 77.18 ± 3.85 | 70.80 ± 3.31 | 70.62 ± 4.11 | |
| 14 days | ||||||
| TC (mg dl−1) | 63.63 ± 4.95 | 143.36 ± 8.01(a) | 71.82 ± 5.30(b) | 122.90 ± 8.18(a),(b),(c) | 108.76 ± 6.67(b),(c),(d) | |
| HDL (mg dl−1) | 35.13 ± 1.98 | 34.75 ± 4.27 | 38.25 ± 4.35 | 38.44 ± 1.62 | 40.50 ± 2.65 | |
| LDL (mg dl−1) | 7.09 ± 7.09 | 15.86 ± 12.92 | 6.14 ± 5.68 | 15.73 ± 4.36 | 13.69 ± 9.78 | |
| VLDL (mg dl−1) | 35.59 ± 1.66 | 92.75 ± 12.67(a) | 39.70 ± 1.62(b) | 68.73 ± 3.90(a),(b),(c) | 51.95 ± 5.70(a),(b),(d) | |
| TG (mg dl−1) | 177.93 ± 8.29 | 463.77 ± 63.37(a) | 198.50 ± 8.10(b) | 373.63 ± 19.48(a),(b),(c) | 299.76 ± 28.49(a),(b),(d) | |
| 36 days | ||||||
| TC (mg dl−1) | 254.86 ± 2.18 | 552.55 ± 42.00(a) | 269.83 ± 11.45(b) | 399.96 ± 41.61(a),(b),(c) | 359.65 ± 41.08(a),(b),(c) | |
| HDL (mg dl−1) | 33.94 ± 2.21 | 32.94 ± 3.56 | 38.00 ± 5.89 | 34.00 ± 4.40 | 37.91 ± 1.64 | |
| LDL (mg dl−1) | 170.49 ± 5.41 | 347.48 ± 32.80(a) | 175.53 ± 9.05(b) | 177.33 ± 39.96(b) | 208.64 ± 42.99(b) | |
| VLDL (mg dl−1) | 50.43 ± 6.57 | 172.13 ± 12.35(a) | 56.29 ± 1.79(b) | 138.63 ± 3.72(b) | 113.10 ± 6.71(a),(b),(c),(d) | |
| TG (mg dl−1) | 252.15 ± 32.84 | 860.65 ± 61.77(a) | 281.46 ± 8.96(b) | 663.16 ± 18.58(a),(b),(c) | 539.50 ± 33.55(a),(b),(c),(d) | |
| 72 days | ||||||
| TC (mg dl−1) | 353.78 ± 5.78 | 868.43 ± 47.98(a) | 384.69 ± 4.94(b) | 604.58 ± 27.42(a),(b),(c) | 543.47 ± 53.91(a),(b),(c),(d) | |
| HDL (mg dl−1) | 34.25 ± 1.71 | 30.00 ± 1.15 | 41.75 ± 4.92(b) | 35.25 ± 2.99 | 38.58 ± 4.38(b) | |
| LDL (mg dl−1) | 252.41 ± 7.47 | 582.44 ± 52.37(a) | 267.06 ± 2.23(b) | 489.17 ± 33.85(a),(b),(c) | 348.02 ± 63.85(a),(b),(d) | |
| VLDL (mg dl−1) | 67.11 ± 3.45 | 255.98 ± 7.82(a) | 75.88 ± 2.25(b) | 180.16 ± 13.48(a),(b),(c) | 156.87 ± 9.58(a),(b),(c),(d) | |
| TG (mg dl−1) | 335.57 ± 17.27 | 1279.92 ± 39.09(a) | 379.38 ± 11.23(b) | 900.79 ± 67.40(a),(b),(c) | 704.36 ± 47.92(a),(b),(c),(d) | |
| Atherogenic Index | 10.32 ± 2.38 | 28.94 ± 2.55 | 9.21 ± 1.02 | 19.98 ± 4.18 | 14.08 ± 3.31 |
Values expressed are mean ± SD of four animals per group.
(a),(b),(c),(d)statistical significance at P < .05 when compared with control, disease control, standard and treatment, respectively, on performing repeated measures ANOVA with Tukey's multiple comparison post hoc test.
Figure 2Atherosclerotic index.
Figure 3Aortic section of the control group rabbit revealing no pathological changes. HE × 5.
Figure 4Thickening of the arterial wall in aortic section of the diseased control group. HE × 10.
Figure 5Presence of normal architecture of the aorta in the standard drug treated group. HE × 10.
Figure 6Low dose treated rabbit aortic section showing moderate thickening of the arterial wall. HE × 10.
Figure 7Aortic section of the high-dose group rabbit showing relatively normal arterial wall. HE × 40.
Figure 8Schematic diagram.